Call for Abstracts

Submission Requirements

Abstract Submission

Submission period:
July 20 (Thu), 2017 at 12pm (JPN time) -
August 29 (Tue), 2017 at 12pm.(JPN time)

New Deadline: September 5 (Tue) at 12pm (JPN time)
Call for Abstracts is now closed.

Abstract submission is accepted only by e-mail.
Please send the abstract to the secretariat via e-mail to: jshct2018@congre.co.jp

Requirements

  • Abstract body word limitation shall be maximum 250 words in English.

    * In case you need to add one image(picture, chart, diagram) in your abstract,
    please reduce the word limitation to 125 words.

  • Please include author’s information; the title, names of all authors and their affiliations, postal and e-mail addresses of the presenting author in addition to the abstract body. Authors are limited to 30.
  • Any submitted abstracts will not be edited or proof-read before printing.
    The first/presenting author is responsible for his/her abstract.
  • Submission Deadline: August 29 (Tue), 2017 at 12 pm (JPN time)

Please send the abstract to the secretariat via e-mail to: jshct2018@congre.co.jp

Presentation style

The Program Committee welcomes abstract submissions for Oral presentation or Poster discussion. Submitted abstracts will be chosen for Oral presentation or Poster discussion depending on the results of peer review.

Notification of Acceptance / Rejection

All abstracts will be reviewed by the Program Committee, and the committee will make the final decision of acceptance/rejection.
Authors will be notified by e-mail of peer review results and detailed information for their presentation.

Disclosure of Conflict of Interest (COI) (related to your Abstract)

Presenting authors are required to report any financial relationship with any commercial entities or for-profit organizations related to the clinical research within the previous 12 months.
The definition of "clinical research" includes all phases of clinical trial and pre-clinical research.

At the time of abstract submission

If the authors have any commercial relationships relevant to the content of the abstract, they are required to report applicable COI to the secretariat.

At the time of presentation

The presenting author is required to disclose applicable COI by displaying a COI disclosure slide at the beginning of presentation slides (the slide after the title of presentation and the name of presenters) or at the end of a poster using samples as attached.

COI COI COI

Ethical Approval

In the case that a presentation theme relates to “Ethical guidelines for Clinical Research”, the approval of the Institutional Review Board (IRB) or the Ethical Review Board (ERB) is required. Please refer to the guideline of the Ministry of Education, Culture, Sports, Science and Technology website.
(http://www.lifescience.mext.go.jp/files/pdf/n1500_01.pdf)

Secretariat

Congress Secretariat
c/o Congress Corporation
Sumitomo-Seimei Sapporo Bldg., 2-12, North 5, West 5,
Chuo-ku, Sapporo, 060-0005, Japan
TEL: +81-11-233-0005 Fax: +81-11-233-0035
E-mail: jshct2018@congre.co.jp